Cargando…
myCOPD App for Managing Chronic Obstructive Pulmonary Disease: A NICE Medical Technology Guidance for a Digital Health Technology
myCOPD is a digital tool designed for people to manage their chronic obstructive pulmonary disease (COPD). It requires a device with an internet connection and incorporates tools for education, self-management, symptom tracking and pulmonary rehabilitation (PR). myCOPD was selected for medical techn...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403412/ https://www.ncbi.nlm.nih.gov/pubmed/37246188 http://dx.doi.org/10.1007/s40258-023-00811-x |
_version_ | 1785085062110248960 |
---|---|
author | Davies, Heather Chappell, Mary Wang, Yingying Phalguni, Angaja Wake, Stephanie Arber, Mick Shore, Judith |
author_facet | Davies, Heather Chappell, Mary Wang, Yingying Phalguni, Angaja Wake, Stephanie Arber, Mick Shore, Judith |
author_sort | Davies, Heather |
collection | PubMed |
description | myCOPD is a digital tool designed for people to manage their chronic obstructive pulmonary disease (COPD). It requires a device with an internet connection and incorporates tools for education, self-management, symptom tracking and pulmonary rehabilitation (PR). myCOPD was selected for medical technologies guidance by the UK National Institute for Health and Care Excellence (NICE) in 2020. The External Assessment Group (EAG) critiqued the company’s submission. The evidence comprised four clinical studies (three randomised controlled trials [RCTs] and one observational study) and real-world evidence from 22 documents. The RCTs had small sample sizes, limiting the power to detect statistically significant differences and to match patient characteristics across arms. The company produced two de novo models for two subgroups of people with COPD; people discharged from hospital with acute exacerbation of COPD (AECOPD) and people referred for PR. After the EAG updated input parameters and adjusted the model structures, cost savings of £86,297 per clinical commissioning group (CCG) compared with standard care were estimated for the AECOPD population, with myCOPD predicted to be cost saving in 74% of iterations. Cost savings of £22,779 per CCG were estimated for the PR population (with the assumption that the CCG had an existing myCOPD licence), with myCOPD predicted to be cost saving in 86% of the iterations. The Medical Technologies Advisory Committee concluded that although myCOPD has the potential to help manage COPD in adults, further evidence is required to address uncertainties in the current evidence base. NICE published this as Medical Technology Guidance 68 (National Institute for Health and Care Excellence (NICE). myCOPD for managing chronic obstructive pulmonary disease. 2022. Available at: https://www.nice.org.uk/guidance/mtg68/). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40258-023-00811-x. |
format | Online Article Text |
id | pubmed-10403412 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-104034122023-08-06 myCOPD App for Managing Chronic Obstructive Pulmonary Disease: A NICE Medical Technology Guidance for a Digital Health Technology Davies, Heather Chappell, Mary Wang, Yingying Phalguni, Angaja Wake, Stephanie Arber, Mick Shore, Judith Appl Health Econ Health Policy Review Article myCOPD is a digital tool designed for people to manage their chronic obstructive pulmonary disease (COPD). It requires a device with an internet connection and incorporates tools for education, self-management, symptom tracking and pulmonary rehabilitation (PR). myCOPD was selected for medical technologies guidance by the UK National Institute for Health and Care Excellence (NICE) in 2020. The External Assessment Group (EAG) critiqued the company’s submission. The evidence comprised four clinical studies (three randomised controlled trials [RCTs] and one observational study) and real-world evidence from 22 documents. The RCTs had small sample sizes, limiting the power to detect statistically significant differences and to match patient characteristics across arms. The company produced two de novo models for two subgroups of people with COPD; people discharged from hospital with acute exacerbation of COPD (AECOPD) and people referred for PR. After the EAG updated input parameters and adjusted the model structures, cost savings of £86,297 per clinical commissioning group (CCG) compared with standard care were estimated for the AECOPD population, with myCOPD predicted to be cost saving in 74% of iterations. Cost savings of £22,779 per CCG were estimated for the PR population (with the assumption that the CCG had an existing myCOPD licence), with myCOPD predicted to be cost saving in 86% of the iterations. The Medical Technologies Advisory Committee concluded that although myCOPD has the potential to help manage COPD in adults, further evidence is required to address uncertainties in the current evidence base. NICE published this as Medical Technology Guidance 68 (National Institute for Health and Care Excellence (NICE). myCOPD for managing chronic obstructive pulmonary disease. 2022. Available at: https://www.nice.org.uk/guidance/mtg68/). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40258-023-00811-x. Springer International Publishing 2023-05-28 2023 /pmc/articles/PMC10403412/ /pubmed/37246188 http://dx.doi.org/10.1007/s40258-023-00811-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Review Article Davies, Heather Chappell, Mary Wang, Yingying Phalguni, Angaja Wake, Stephanie Arber, Mick Shore, Judith myCOPD App for Managing Chronic Obstructive Pulmonary Disease: A NICE Medical Technology Guidance for a Digital Health Technology |
title | myCOPD App for Managing Chronic Obstructive Pulmonary Disease: A NICE Medical Technology Guidance for a Digital Health Technology |
title_full | myCOPD App for Managing Chronic Obstructive Pulmonary Disease: A NICE Medical Technology Guidance for a Digital Health Technology |
title_fullStr | myCOPD App for Managing Chronic Obstructive Pulmonary Disease: A NICE Medical Technology Guidance for a Digital Health Technology |
title_full_unstemmed | myCOPD App for Managing Chronic Obstructive Pulmonary Disease: A NICE Medical Technology Guidance for a Digital Health Technology |
title_short | myCOPD App for Managing Chronic Obstructive Pulmonary Disease: A NICE Medical Technology Guidance for a Digital Health Technology |
title_sort | mycopd app for managing chronic obstructive pulmonary disease: a nice medical technology guidance for a digital health technology |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403412/ https://www.ncbi.nlm.nih.gov/pubmed/37246188 http://dx.doi.org/10.1007/s40258-023-00811-x |
work_keys_str_mv | AT daviesheather mycopdappformanagingchronicobstructivepulmonarydiseaseanicemedicaltechnologyguidanceforadigitalhealthtechnology AT chappellmary mycopdappformanagingchronicobstructivepulmonarydiseaseanicemedicaltechnologyguidanceforadigitalhealthtechnology AT wangyingying mycopdappformanagingchronicobstructivepulmonarydiseaseanicemedicaltechnologyguidanceforadigitalhealthtechnology AT phalguniangaja mycopdappformanagingchronicobstructivepulmonarydiseaseanicemedicaltechnologyguidanceforadigitalhealthtechnology AT wakestephanie mycopdappformanagingchronicobstructivepulmonarydiseaseanicemedicaltechnologyguidanceforadigitalhealthtechnology AT arbermick mycopdappformanagingchronicobstructivepulmonarydiseaseanicemedicaltechnologyguidanceforadigitalhealthtechnology AT shorejudith mycopdappformanagingchronicobstructivepulmonarydiseaseanicemedicaltechnologyguidanceforadigitalhealthtechnology |